Intensive insulin for type 2 diabetes: The risk of causing harm

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 1, 2013, Pages 9-10

  Nolan, Christopher J ^a   Ruderman, Neil B ^b   Prentki, Marc ^c  

^a The Australian National University   (Australia)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DRUG MEGADOSE; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; METABOLIC STRESS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; WEIGHT GAIN; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; PHYSIOLOGY; PROCEDURES; RISK FACTOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; RISK FACTORS;

EID: 84882572778     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70027-5     Document Type: Letter

References (10)

1. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
2. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
3. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3·4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010, 33:983-990.
4. Kraegen EW, Saha AK, Preston E, et al. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006, 290:E471-E479.
5. Nolan CJ, Damm P, Prentki M Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378:169-181.
6. Taegtmeyer H, Stanley WC Too much or not enough of a good thing? Cardiac glucolipotoxicity versus lipoprotection. J Mol Cell Cardiol 2010, 50:2-5.
7. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001, 103:1734-1739.
8. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
9. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011, 54:1308-1317.
10. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in Type 2 Diabetes. J Clin Endocrinol Metab 2013, 98:668-677.